TriangleSacituzumab Govitecan + Cisplatin (NCT06040970)
Sacituzumab Govitecan + Cisplatin trial for Platinum-Sensitive Recurrent Ovarian and Endometrial Cancer (NCT06040970). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with recurrent ovarian or endometrial cancer that is platinum sensitive.
The idea: combine the drug sacituzumab govitecan with the chemotherapy cisplatin, both given by vein. The study sets the best dose of sacituzumab govitecan for use with cisplatin, then expands in ovarian and endometrial cancer groups.
This phase 1 and 2 study plans 54 patients and looks at dose limiting side effects. At the Icahn School of Medicine at Mount Sinai in New York, Amy Tiersten leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.